Profile

Susan A. Melin, M.D.Wake Forest Baptist Health

Doctor Rating

4.6 out of 5

139 Ratings
12 Comments
 

Susan A. Melin, M.D.

Professor,

Clinical Interests

Breast Cancer

Contact Information

Returning Patient Appointments: 336-713-5440
Department: 336-716-4464

Insurance Accepted »

Education & Training

  • B.S., University of North Carolina-Chapel Hill, 1977
  • M.D., WFU School of Medicine, 1985
  • Residency, Eastern Virginia Med School, 1988
  • Fellowship, Univ of NC at Chapel Hill, 1991

Board Certifications

  • American Board of Internal Medicine, Hematology
  • American Board of Internal Medicine, Internal Medicine
  • American Board of Internal Medicine, Medical Oncology

Memberships

  • North Carolina Medical Society
  • Am Coll Of Physicians
  • Am Medical Assn
  • Am Soc of Clinical Oncology

NPI Number

  • 1528042058
Susan A. Melin, M.D.

Doctor Rating

4.6 out of 5

139 Ratings
12 Comments
 

Susan A. Melin, M.D.

Professor, Hematology & Oncology
Office of Women in Medicine and Science

Research Interests

Antineoplastic Agents; Anthracyclines; Thalidomide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms
More »

Contact Information

Academic: 336-716-7975 | Department: 336-716-4464

Recent Publications

A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer. Cowherd S, Miller LD, Melin SA, Akman S, Isom S, Cole J, Pullikuth A, Lawrence JA.. Cancer Biol Ther. 2015;16(5):678-683.

Weight loss intervention in survivors of ER/PR-negative breast cancer. Vitolins MZ, Milliron BJ, Hopkins JO, Fulmer A, Lawrence J, Melin S, Case D.. Clin Med Insights Womens Health. 2014;7():17-24.

Does age predict outcome in patients with inflammatory breast cancer?. Ahmed S, Lawrence J, Stewart JH, Melin S, Levine EA, Howard-McNatt M.. Am Surg. 2014;80(8):E221-E224.

A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic or recurrent breast cancer patients with triple negative disease [abstract]. Cowherd S, Melin S, Akman S, Cole J, Lawrence J.. Cancer Res. 2014;74(19 Suppl):CT302.

Race and recurrence in women who undergo neoadjuvant chemotherapy for breast cancer. Howard-McNatt M, Lawrence J, Melin SA, Levine EA, Shen P, Stewart JH IV.. Am J Surg. 2013;205(4):397-401.

The Dignicap System to prevent alopecia in women receiving chemotherapy for breast cancer [abstract]. Rugo HS, Serrurier K, Melisko M, Glencer A, Hwang J, D'Agostino R, Hutchens S, Esserman L, Melin S.. Breast. 2013;22(Suppl 1):S119.

Oral paricalcitol (19-nor-1,25-dihydroxyvitamin D2) in women receiving chemotherapy for metastatic breast cancer: a feasibility trial. Lawrence JA, Akman SA, Melin SA, Case LD, Schwartz GG.. Cancer Biol Ther. 2013;14(6):476-480.

Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. Drafts BC, Twomley KM, D'Agostino R Jr, Lawrence J, Avis N, Ellis LR, Thohan V, Jordan J, Melin SA, Torti FM, Little WC, Hamilton CA, Hundley WG.. JACC Cardiovasc Imaging. 2013;6(8):877-885.

Aortic stiffness increases upon receipt of anthracycline chemotherapy. Chaosuwannakit N, D'Agostino R Jr, Hamilton CA, Lane KS, Ntim WO, Lawrence J, Melin SA, Ellis LR, Torti FM, Little WC, Hundley WG.. J Clin Oncol. 2010;28(1):166-172.

Self-reported compliance compared to biomarker levels of vitamin E in breast cancer patients participating in a CoQ10 clinical trial [abstract]. Vitolins M, Lesser GJ, Case LD, Williford SK, Giguere JK, Garino A, Naughton MJ, Lively M, Melin SA, Shaw EG.. J Clin Oncol. 2010;28(15 Suppl):e19524.

Early and persistent evidence of subclinical cardiovascular injury after receipt of anthracycline chemotherapy [abstract]. Twomley K, D'Agostino R Jr, Lawrence J, Melin S, Ellis LR, Stacey B, Hamilton CA, Torti F, Little W, Hundley W.. Circulation. 2010;122(21 Suppl):A12766.

Subclinical cardiovascular toxicity of anthracyclines identified with cardiovascular magnetic resonance imaging [abstract]. Chaosuwannakit N, D'Agostino R Jr, Hamilton CA, Lane KS, Ntim WO, Lawrence J, Melin SA, Ellis LR, Torti FM, Little WC, Hundley WG.. Circulation. 2009;120(18 Suppl):S299.

A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer. Ramanathan RK, Picus J, Raftopoulos H, Bernard S, Lockhart AC, Frenette G, Macdonald J, Melin S, Berg D, Brescia F, et al.. Cancer Chemother Pharmacol. 2008;61(3):453-458.

Phase I study of lenalidomide in solid tumors. Miller AA, Case D, Harmon M, Savage P, Lesser G, Hurd D, Melin SA.. J Thorac Oncol. 2007;2(5):445-449.

Tri-modality therapy for esophageal cancer: mucinous histology is associated with decreased pathologic response rates to neoadjuvant chemoradiation therapy [abstract]. Kim C, Farmer MR, Yacoub J, Monjazeb A, Levine EA, Aklilu M, Geinsinger [sic] KR [Geisinger KR], Mishra G, Melin S, Blackstock AW.. Int J Radiat Oncol Biol Phys. 2007;69(3 Suppl):S267.

Patterns of failure for esophageal cancer patients optimally staged with 18-F-FDG-PET and observed after chemo-radiotherapy [abstract]. Monjazeb AM, Farmer MR, Mattern M, Mebea A, Levine EA, Geisinger KR, Mishra G, Melin S, Blackstock AW.. Int J Radiat Oncol Biol Phys. 2007;69(3 Suppl):S274.

Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. Blackstock AW, Mornex F, Partensky C, Descos L, Case LD, Melin SA, Levine EA, Mishra G, Limentani SA, Kachnic LA, et al.. Br J Cancer. 2006;95(3):260-265.

Pathologic complete response may not represent the optimal surrogate for survival after preoperative therapy for esophageal cancer. Blackstock AW, Aklilu M, Lovato J, Farmer MR, Mishra G, Melin SA, Oaks T, Geisinger K, Levine EA.. Int J Gastrointest Cancer. 2006;37(1):7-14.

Tri-modality therapy for esophageal cancer: hemoglobin levels are prognostic for survival but do not predict response to radiochemotherapy [abstract]. Farmer MR, Yacoub J, Aklilu M, Levine EA, Geisinger K, Mishra G, Melin S, Blackstock AW.. Int J Radiat Oncol Biol Phys. 2006;66(3 Suppl):S269.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, Hematology & Oncology

Clinical Interests

Breast Cancer
Susan A. Melin, M.D.

Susan A. Melin, M.D.

Professor, Hematology & Oncology
Office of Women in Medicine and Science

Doctor Rating

4.6 out of 5

Susan A. Melin, M.D.139 Ratings
12 Comments


 

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
4.7
CP efforts to include in decisions
4.8
CP explanations of prob/condition
4.8
CP spoke using clear language
4.8
Friendliness/courtesy of CP
4.8
Likelihood of recommending CP
4.8
Patients' confidence in CP
4.8
Time CP spent with patient
4.6
Wait time at clinic
3.2



Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.

8/24/2016

Takes an entire day for an appointment.

8/22/2016

dr melin is most excellent - best physician I have (& I have a few!). love love her...will call after hours...truly cares for her patients.

8/18/2016

This doctor is condescending, sarcastic and disrespectful. She rolls her eyes at any questions I ask and seems very irritated by them.

8/2/2016

Never talked about any of my issues.

7/28/2016

I think something *Dr. Melin assumes that because I am highly educated, I will understand all of her medical vocabulary - but I am not well _____ IN MEDICINE & sometimes have to ask her to explain.

7/12/2016

Dr Melin has twice extended my life significantly. I am very grateful for her expertise.

5/10/2016

Everyone is great.

2/24/2016

I have great doctors, that show a lot of concern for my care..

2/22/2016

My provider is great she always takes time to answer questions and she's very considerate she has a very good and sweet spirit and she's smart.????

2/15/2016

waited too long and didn't spend much time with patient.

2/4/2016

I have the utmost confidence in Dr. Melin.

12/15/2015

Dr. Susan Melin has picked up on important health issues, unrelated to Oncology, on two occasions. She immediately ordered scans or tests related to the concerns. In both cases, the concerns were valid.

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
Comprehensive Cancer Centers National Designation is RenewedMagnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.